CRP as a marker of inflammation: Mitigation of Ulcerative Colitis in rats by Mesalazine and Coenzyme Q10.

Background: Ulcerative colitis is a global health issue with no definitive treatment options available. Mesalazine is one of the first-line therapies available, and Coenzyme Q10 is a cellular component with anti-inflammatory, antioxidant, and cell-healing properties. This study evaluated the anti-inflammatory potential of mesalazine and Coenzyme Q10, alone and in combination, and C-reactive protein was assessed as a parameter of acute inflammation. Methods: 48 rats were divided into 6 groups. Ulcerative colitis was experimentally induced in rats and mesalazine and Coenzyme Q10 were given alone and in combination according to the grouping of animals. The kit method measured C-reactive protein levels in serum after 7 days. Results: the group treated with a combination of mesalazine and coenzyme Q10 showed a maximum reduction in C-reactive protein levels with only 12.5% with positive or >6mg/dl levels as compared to 100% with positive or >6mg/dl value in the disease-control group. Conclusion: The study showed that the combination of mesalazine and coenzyme Q10 has synergistic potential in reducing inflammation in ulcerative colitis.